Kornimate/medical-research-clean huggingface dataset:
study of the adequacy between calcium supplementation and dietary intake in treatment-naive patients after a fracture

Conditions: Osteoporosis, Post-Traumatic; Calcium Supplementation; Osteoporosis, Management Care, Fracture

Summary: osteoporosis is a disease that causes many fractures. however, treatments exist such as anti-osteoporotic treatments, vitamin d supplementation and an adaptation of calcium intake. 80% of patients with an indication for anti-osteoporotic treatment are never treated with these anti-osteoporotic treatments after a first fracture. on the other hand, more than 84% of them are supplemented with calcium and vitamin d. it often appears in the practice of rheumatologists that some patients are supplemented while their dietary intake is sufficient, and vice versa. the objective of the study is therefore to take stock of the (in)adequacy between the dietary intake of patients and the supplementation prescribed to them following an osteoporotic-like fracture.


Eligibility criteria:
inclusion criteria: * patient meeting a first rheumatologist after a fracture suspected of being due to bone insufficiency, whether or not he is already treated for osteoporosis * age ≥ 18 years * patient followed in one of the three investigation centers within the framework of the bone sector. * patient affiliated to a social security system exclusion criteria: * patient refusing to participate in the study * patient already followed by a rheumatologist * legal incapacity or any physical, psychological, social or geographical condition likely to hinder the patient's ability to participate in the study
the safety and efficacy of an investigational drug in delaying the progression of alzheimer's disease

Conditions: Alzheimer Disease

Summary: this is a 15-month study with two phases. during the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). the second phase is a 3-month randomized withdrawal period. for this phase approximately 10% of the patients will remain on the active drug.

this is a placebo-controlled, parallel-groups, 12 month, double-blind study, followed by a 3-month, double-blind, randomized withdrawal period to evaluate the efficacy and safety of an investigational drug (currently approved for other indications) to slow the progression of symptoms of ad. patients with probable ad according to nincds-adrda criteria who have a mini mental state examination (mmse) score between 13 and 26 inclusive will be eligible for participation in the study. patients on stable doses of marketed cholinesterase inhibitors approved for the treatment of ad (except for tacrine) for at least 3 months are eligible for study entry. use of nsaids (except aspirin 81 mg per day) is not allowed during the study.

Eligibility criteria:
inclusion criteria: * patient is male or female and at least 50 years of age or older * female patients must be postmenopausal or surgically sterilized * clinical diagnosis of ad * patient must be in good health except for ad diagnosis * patient must have informant/caregiver who can monitor and assist patient during the study exclusion criteria: * patient is living in a nursing home or skilled nursing facility * women will be ineligible if not postmenopausal or surgically sterilized * site physician or sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma

Keywords: investigational drug
persistence of bactericidal antibodies in adults who received a booster dose of menactra® approximately 4 years earlier

Conditions: Meningitis; Meningococcal Meningitis; Meningococcal Infections

Summary: the aim of this study is to provide information on the persistence of bactericidal antibodies following menactra booster vaccination in study mta77 ( nct01442675). objective: * to evaluate the persistence of antibody responses (determined by a serum bactericidal assay using human complement (sba-hc)) approximately 4 years after the administration of a booster dose of menactra vaccine in trial mta77

all eligible subjects will provide 1 blood sample at visit 1. the duration of each subject's participation in the trial will be the duration of 1 visit (for enrollment and blood draw)

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years on the day of inclusion * received booster dose of menactra vaccine in trial mta77 * informed consent form has been signed and dated * able to attend the scheduled visit and to comply with all trial procedures. exclusion criteria: * participation at the time of trial enrollment (or in the 4 weeks preceding trial enrollment) in another clinical trial investigating a vaccine, drug, medical device, or medical procedure * receipt of any meningococcal vaccine, including serogroup b meningococcal vaccine, after receipt of the booster dose of menactra vaccine administered in trial mta77 * receipt of immune globulins, blood or blood-derived products in the past 3 months * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * history of meningococcal infection, confirmed either clinically, serologically, or microbiologically * bleeding disorder, thrombocytopenia, or receipt of anticoagulants contraindicating venipuncture at the discretion of the investigator * deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily * current alcohol abuse or drug addiction * any illness that, in the opinion of the investigator, might interfere with trial conduct or trial results * receipt of oral or injectable antibiotic therapy within 72 hours prior to the blood draw. (a prospective subject should not be included in the trial until 72 hours has passed.) * identified as an investigator or employee of the investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed trial.

Keywords: meningitis meningococcal meningitis meningococcal infections menactra®
fish oil supplementation and vascular function in hypertensive patients with hypertriglyceridemia

Conditions: Hypertension; Hypertriglyceridemia

Summary: the objective of this study is to compare the effects of ciprofibrate versus omega-3 fatty acid supplementation on the vascular structure and function in hypertensive patients with hypertriglyceridemia.

hypertensive patients aged 40-65 years, both genders, presenting serum triglycerides levels higher than 150 mg/dl will be randomized into two groups. the first group will be receiving ciprofibrate 100mg/day and the second group will be receiving fish oil 1800mg/day. all patients will be evaluated with brachial flow-mediated dilation and with endopat to assess endothelial function before and after supplementation. sphygmocor and pulse wave velocity (pwv) measurements will also be obtained.

Eligibility criteria:
inclusion criteria: * previous diagnosis of hypertension * patients with serum triglycerides levels ≥ 150 mg/dl and \<500 mg/dl * patients on stable antihypertensive medication for at least 4 weeks * patients with food consumption maintained for at least 4 weeks exclusion criteria: * smoking * secondary hypertension * hormone replacement therapy * diabetes mellitus * chronic kidney disease * known coronary artery disease * previous stroke * dyslipidemia severe, with ldl cholesterol\> 160 mg/dl or triglycerides ≥ 500 mg/dl * use of statins or beta blockers

Keywords: hypertension endothelial dysfunction vascular stiffness
repetitive transcranial magnetic stimulation and intermittent theta burst (itbs) in schizophrenia

Conditions: Schizophrenia

Summary: the pilot studies have showed that theta burst stimulation (tbs) can have the more rapid and durable effects to the apply traditional rtms protocols. the aim of this study is to investigate the effect of repetitive tms and theta burst in reduction of negative symptoms and remission of cognitive functioning in patients with schizophrenia. in a randomized, double blind clinical trials, 30 patients with schizophrenia in razi psychiatric hospital will be assigned to receive repetitive tms; theta burst, or sham tms, daily; for 20 sessions. the negative symptoms and cognitive functioning will be assessed before the treatment (pre test) during the treatment (session 10), and after the treatment (post test).qeeg and loreta apply before and after rtms in all subjects.


Eligibility criteria:
inclusion criteria: 1. outpatients male and female with the range of 18-50 years of age 2. the diagnosis of schizophrenia according to dsm-iv-tr 3. completion of consent form 4. being under supervision of a psychiatrist, 5. being able to adhere to treatment schedule, 6. having stable symptoms as defined by not requiring a change in antipsychotic medication for at least 4 weeks or at least 2 weeks for psychotropic agents prior to entering the study exclusion criteria: 1. the history of rtms treatment for any reason 2. cardiac pacemaker 3. drug pumps 4. acute heart attack 5. the risk of seizure with any reasons 6. the history of epilepsy or seizure in the first relatives 7. any metal in head 8. brain trauma 9. pregnancy 10. breastfeeding 11. drug dependency
treatment of cerebellar ataxia with mesenchymal stem cells

Conditions: Cerebellar Ataxia

Summary: the study is to investigate the efficacy and safety of allogenous transplantation of adipose-derived mesenchyma stem cells in patients with cerebellar ataxia.


Eligibility criteria:
inclusion criteria: * patients diagnosed of spinocerebellar ataxia 3 (sca3) or multiple system atrophy-cerebellar (msa-c). * subject's sara score at 10\~20 points. * ages between 20\~70 years. * signed informed consent from the patient and/or guardian. exclusion criteria: * subjects enrolled in any other cell therapy studies within the past 30 days. * pregnancy test positive. * subjects deemed to be not suitable for the study by the investigator.
performances of a brief assessment tool for the early diagnosis of geriatric syndromes by primary care physicians

Conditions: Cognitive Impairment; Mood Disorders; Urinary Incontinence; Malnutrition; Osteoporosis; Hearing Impairment; Visual Impairment

Summary: the age (active geriatric evaluation) aims to develop a brief assessment tool adapted to the primary care setting.

the age (active geriatric evaluation) program is a collaborative project between a primary care institution and a specialised geriatric unit that aims to develop a brief assessment tool (bat) adapted to the primary care setting. the objective of this study is to assess the performances of the bat to identify major geriatric syndromes: cognitive impairment; mood disorder; functional impairment; urinary incontinence; malnutrition; gait and balance impairment; osteoporosis; hearing impairment; visual impairment. in order to achieve our objective, we plan to recruit 155 patients \> 70 years old in primary care settings for which primary care physicians will perform the bat (composed of specific questions and clinical exams). at the end of the consultation, the primary care physician will fill a questionnaire where the absence/presence of syndromes will be recorded (according to the findings of the bat). each patient will be then seen a second time by expert geriatricians that will perform a full geriatric evaluation (90 minutes). this will allow to calculate the performances of the intervention (bat) in terms of sensibility /specificity,...

Eligibility criteria:
inclusion criteria: * age \> 70 years * follow-up by general practitioner * good understanding of french or presence of a translater * no previous or on-going geriatric consultation * patient able to provide consent or a relative is present that can provide a consent instead exclusion criteria: * age \< 70 years * no follow-up by general practitioner * unable to understand french or absence of a translater * on-going geriatric follow-up * patient unable to provide consent or a relative is absent
patent versus generic clopidogrel in acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: ischemic heart disease is the leading cause of death and disability in developed countries and is responsible for a third of deaths in persons over 35 years . the most severe form of ischemic heart disease is sudden death and acute coronary syndrome (acs). there is evidence that early and optimal treatment of acs decreases mortality. within the optimal treatment, these patients must receive a reperfusion therapy as mechanical or pharmacologic treatment. in addition to reperfusion treatment, antiplatelet therapy is a central part of the management. aspirin plus a p2y12 inhibitor have been shown to decrease mortality. in our country, clopidogrel is the more accessible and used p2y12 inhibitor; however, it has been shown to have a wide variability in response and this variability could be influenced by different pharmacological, genetic and environmental factors. platelet reactivity measured by aggregometry predicts major cardiovascular events in acs patients treated with clopidogrel. due to their frequent prescription, generic clopidogrel efficacy must be evaluated. the purpose of this study is to compare the platelet reactivity in patients with acs receiving clopidogrel generic versus patent.


Eligibility criteria:
inclusion criteria: * 18 and over * diagnosis of acute coronary syndrome * patients receiving 300 mg of clopidogrel load and a single dose of 75 mg daily * signature of informed consent exclusion criteria: * active bleeding or absolute contraindication for antiplatelet use * chronic kidney disease with creatinine clearance \<30 ml / min * liver damage documented as elevated aspartate aminotransferase/alanine aspartate 2 times upper normal limit (unl) and/or total bilirubin \> 2 times unl * prescribed antiplatelet therapy, other than aspirin

Keywords: acute coronary syndrome clopidogrel platelet reactivity
dexamethasone tolerability in the treatment of acute asthma in children

Conditions: Asthma

Summary: the purpose of this study is to assess whether smaller volumes of oral dexamethasone result in better tolerability, specifically less vomiting, in pediatric patients during an acute asthma exacerbation.


Eligibility criteria:
inclusion criteria: * acute asthma exacerbation * requiring oral systemic corticosteroids for management exclusion criteria: * preference for pills over liquid formulation * history of nissen fundoplication surgery * needed immediate airway intervention * require oral medications to be given via a g or j tube * if patient care would be compromised * enrolled in the study on a previous visit.

Keywords: pediatric dexamethasone management corticosteroids asthma
honey and nigella sativa in covid-19 prophylaxis

Conditions: Covid19

Summary: honey and nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. so it is planned to test for its prophylaxis


Eligibility criteria:
inclusion criteria: * health care professionals post-exposure covid-19 exclusion criteria: * multi-organ failure active covid-19

Keywords: honey nigella sativa prophylaxis covid-19 prophetic medicine
public support for covid-19 test allocation

Conditions: Health Equity; COVID-19

Summary: in a randomized survey experiment, investigators will assess public support or opposition towards one of three potential government plans for allocating at-home coronavirus disease 2019 (covid-19) tests to united states residents: 1) first come, first served; 2) a random draw; or 3) a random draw with 20% of tests reserved for disadvantaged areas. investigators will also examine public attitudes surrounding other logistical and equity-related aspects of these allocation plans.

complementing other efforts to increase access to covid-19 testing in the united states, the federal government recently announced the purchase of 500,000,000 at home covid-19 to be distributed for free "to americans that want them". a central logistical element in matching supply with demand will be a website, on which people will register their interest in getting tests delivered to their home address. however, it is still unclear how supply will be matched with demand. three main candidate options are first come, first served (fcfs), in which people are sent tests in the order in which they make requests; a random draw, such as a lottery; or a combination of a random draw with a guaranteed reserved amount for more disadvantaged populations. fcfs is a widely known and practiced rationing principle, but it has shown to exacerbate inequities in, for example, the allocation of vaccine appointments. random draws can mitigate this impact, but, in the present context, might be insufficiently sensitive to the fact that not everyone has internet access, and that the need for testing is greater among more disadvantaged communities. combining a lottery with a disadvantage reserve system using measures such as the cdc's social vulnerability index is a practical way of promoting equity, and it was already used by the majority of us states in allocating vaccines. the main objective of this study is to assess public support for each of these three allocation plans and describe differences by demographic characteristics. investigators will also assess public attitudes toward specific details of these allocation plans. the study, which is expected to take approximately 5 minutes to complete, will be administered as part of an omnibus online survey.

Eligibility criteria:
inclusion criteria: * aged 18 years old or older, united states resident exclusion criteria: * none

Keywords: allocation of healthcare resources
to compare and evaluate the efficacy and safety of ganilever pfs(prefilled syringe) and orgalutran®

Conditions: Controlled Ovarian Stimulation

Summary: to compare and evaluate the efficacy and safety of ganilever pfs and orgalutran® in infertility women for assisted reproductive technologies


Eligibility criteria:
inclusion criteria: * an adult female between the ages of 20 and 39 at the time of screening * patients whose mean menstrual cycle was between 25 and 35 days * patients whose fsh (follicle stimulating hormone) concentration does not exceed 13 miu / ml at screening * patients diagnosed with infertility due to one or more of the following a. trouble factors b. male factors c. unexplained d. uterine factors * patients with previous ivf experience less than 3 * patient who signed the written consent after hearing the explanation of the purpose, method and effect of the clinical trial exclusion criteria: * if the sperm donor (spouse or non-spouse) is a severe male factor (non obstructive azoospermia) * patients who were diagnosed as pcos (polycystic ovary syndrome) during screening * patient with abnormal uterine bleeding during screening * patients diagnosed with primary ovarian failure * patients who has ovarian cysts that are not related to pcos during screening * patients with tubal hydrops * patients with untreated non-reproductive endocrine disease * patients with a deformity of the reproductive organs that can not be conceived, or fibroids of the uterus that can not be conceived (only for submucosal myoma) * patients with less than 2 ovaries (0 or1) * patients with ovarian, breast, uterus, hypothalamus, or pituitary malignancies * patients with bmi \ 30 * patients with an lh concentration of less than 1.2miu / ml during screening * poor ovarian responder by bologna criteria * patients with moderate or severe renal impairment (creatinine clearance \ 5 times normal) * patients who experienced grade 4 or higher ohss (ovarian hyperstimulation syndrome) before * patients who are contraindicated for pregnancy * patients being pregnant or lactating * patients with hypersensitivity to ip * patients who have participated in other medication-related clinical trials since enrollment in this study, or have participated in other clinical trials within 3 months (90 days) before enrolling in this trial
consortium for radiologic imaging studies of polycystic kidney disease

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: the division of kidney urology and hematology disease (dkuhd) of the national institute of diabetes and digestive and kidney diseases (niddk) funded a cooperative agreement (uo1) for a consortium of participating clinical centers (pccs) and a data coordinating and imaging analysis center (dciac) to develop and implement studies to test whether imaging techniques can provide accurate and reproducible markers of progression of renal disease in patients with polycystic kidney disease. the awarded participating clinical centers are emory university, university of kansas, and mayo foundation (with a subcontract to the university of alabama). the awarded dciac is washington university in st. louis. due to the relocation of the dciac p.i. from washington university to the university of pittsburgh, the dciac for crisp ii is located at the university of pittsburgh.

the goal of the crisp study is to conduct a prospective, longitudinal trial to evaluate the accuracy and validity of magnetic resonance imaging to determine disease progression in adpkd defined as a change in both renal and renal cyst volumes and renal function over time.

Eligibility criteria:
inclusion criteria: 1. crisp i participants will be invited to participate in crisp ii. at entry into crisp i participants met a number of inclusion and exclusion criteria. exclusion criteria: 1. current psychiatric or addiction or non-compliance disorder that in the discretion of the principal investigator indicates that the subject will not successfully complete the study; 2. current medical problem that in the discretion of the principal investigator would make unsafe the participation in the study; 3. inability to provide written informed consent

Keywords: autosomal dominant polycystic kidney disease adpkd kidney biomarker mri
investigate the effect of food on the pharmacokinetics of jlp-1310 in healthy male volunteers

Conditions: Diabetes; Hyperlipidemia

Summary: a randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of jlp-1310 in healthy male volunteers.

a randomized, open-label, single dose, crossover clinical trial.

Eligibility criteria:
inclusion criteria: 1. healthy male volunteer, age is over 19 years 2. body weight is over 55kg, the result of body mass index(bmi) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2 3. subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial 4. subject who has the ability and willingness to participate the whole period of trial exclusion criteria: 1. presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. 2. subjects who are allergic to investigational drug. 3. subjects who have a medical history which can affect the clinical trial. 4. hypertension(systolic bp ≥ 140mmhg or diastolic bp ≥ 90mmhg), liver enzyme (ast, alt) level exceeds the maximum normal range more than one and a half times. 5. history of drug abuse or positive drug screening. 6. participation in other drug studies within 3 months prior to the drug administration. 7. whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.